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Abstract
Pseudomonas aeruginosa causes severe sight-threatening corneal infections, with the inflammatory response to the
pathogen being the major factor resulting in damage to the cornea that leads to loss of visual acuity. We found that mice
deficient for macrophage migration inhibitory factor (MIF), a key regulator of inflammation, had significantly reduced
consequences from acute P. aeruginosa keratitis. This improvement in the outcome was manifested as improved bacterial
clearance, decreased neutrophil infiltration, and decreased inflammatory responses when P. aeruginosa-infected MIF knock
out (KO) mice were compared to infected wild-type mice. Recombinant MIF applied to infected corneas restored the
susceptibility of MIF deficient mice to P. aeruginosa-induced disease, demonstrating that MIF is necessary and sufficient to
cause significant pathology at this immune privileged site. A MIF inhibitor administered during P. aeruginosa-induced
infection ameliorated the disease-associated pathology. MIF regulated epithelial cell responses to infection by enhancing
synthesis of proinflammatory mediators in response to P. aeruginosa infection and by promoting bacterial invasion of
corneal epithelial cells, a correlate of virulence in the keratitis model. Our results uncover a host factor that elevates
inflammation and propagates bacterial cellular invasion, and further suggest that inhibition of MIF during infection may
have a beneficial therapeutic effect.
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Introduction
Eye trauma and contact lens wear are the main factors that
predispose to the development of infectious keratitis associated
with vision loss and blindness [1,2]. The organism most often
isolated from contact lens associated corneal ulcers is Pseudomonas
aeruginosa [3,4]. Existing therapies often fail to control the excessive
tissue damage that is induced during P. aeruginosa infection [5].
While antibiotic treatment reduces the bacterial burden, tissue
damage still occurs as a result of an poorly-controlled local
inflammation. Hence, new therapeutic modalities are needed to
control the inflammatory response in addition to the antibiotic
treatments. We hypothesized that the innate immunity factor–
MIF (NP 002406)–could promote the pathogenic consequences of
P. aeruginosa infection by potentiating local inflammation, and, if so,
could be a suitable drug target for treatment.
MIF is an innate immunity molecule with ubiquitous tissue
expression leading to induction of proinflammatory activities. MIF
was originally described as a regulator of macrophage responses
[6]. It directly or indirectly promotes expression of a large panel of
pro-inflammatory cytokines including TNF-a (P01375), IFN-c (P
01579), IL-1b (NP 000566), IL-2 (AAA 59140), IL-6 (CAG 29292),
IL-8 (CAG 46948), MIP-2 (AAF 78449), NO, COX2 (P 00403),
products of the arachidonic acid pathway and matrix metallopro-
teinases [7]. Interestingly, low levels of MIF can override the
anti-inflammatory properties of glucocorticoids by reversing the
inhibitory effect of glucocorticoid on production of TNF-a, IL-1b,
IL-6 and IL-8 [8]. Detailed studies performed in the rat have
shown that preformed MIF protein is released into the circulation
within 6 hrs of LPS injection [9]. LPS toxicity is exacerbated by
co-injection of recombinant MIF (rMIF) with LPS, whereas
neutralization of MIF activity reduces the circulating levels of
TNF-a by 50% and rescues mice from lethal LPS-induced
endotoxic shock [10,11]. All these properties of the MIF molecule
suggest that MIF has a prominent regulatory role related to
inflammation, likely with a critical function as an effector molecule
that is active early in the course of infection with a pathologic
function when continued production exacerbates inflammation,
giving rise to attendant tissue pathology.
The contribution of MIF during responses to infections by a
variety of pathogens, including bacteria, viruses, and parasites is
currently an area of active research. Recent clinical correlative
studies have demonstrated increased MIF levels and elevated MIF-
dependent proinflammatory cytokines are produced during H1N5
influenza infection, dengue fever, and bacterial urinary tract
infections [12,13,14]. These results demonstrate an important
contribution of MIF to the pathogenesis of viral or bacterial
induced inflammation and suggest a possible beneficial role of
neutralizing MIF as an adjunctive therapeutic approach to treat
the severe forms of disease.
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consequent inhibition of cellular migration has supported the
conclusion that MIF contributes to the establishment of the eye’s
immune privilege status due to immunosuppressive activities
[15,16,17,18]. While this could be important in the resting state,
the strong impact MIF has on induction of inflammation in
response to infection suggests a different role for this molecule
during active infection. In this study, we tested whether inhibition
of MIF in the eye led to a decrease in P. aeruginosa-induced
pathology, and if this was associated with decreased PMN
infiltration and thus decreased inflammation and corneal pathol-
ogy. Overall, we found that inhibition of MIF had a pronounced
salutary effect on eye pathology emanating from P. aeruginosa
keratitis, which we associated with a better ability of PMN from
MIF-deficient mice to mediate opsonic killing of this organism,
making MIF a promising therapeutic target to control local
inflammation in the context of P. aeruginosa corneal infection.
Results
Bacterial burdens after Pseudomonas aeruginosa eye
infection are elevated in WT mice compared with MIF KO
mice
To determine the effect of MIF on P. aeruginosa-induced keratitis,
MIF KO and C57Bl6 WT mice were infected with P. aeruginosa
strain 6294 and the bacterial levels in the corneas of mice
measured to monitor disease progression. At 24 h after onset of
infection there were modest but significantly (P=0.04) lower
bacterial levels in both the extracellular and intracellular samples
from the corneas of the infected MIF KO mice when compared to
C57Bl6 control animals (Fig. 1A). However, the corneal pathology
scores of MIF KO and C57Bl6 were comparable at 24 h.
At 48 h after infection the differences between the MIF KO and
C57Bl6 mice increased dramatically: there were about 100-fold
fewer bacteria recovered from the corneal cell exterior in the
infected MIF KO mice compared to the C57Bl6 controls. Even
more dramatically, about 10,000 less intracellular bacteria were
recovered from MIF KO mice when compared to C57Bl6 mice
(Fig. 1B). Consistent with the reduced bacterial levels, the MIF
KO mice infected with P. aeruginosa strain 6294 had a significant
decrease in corneal pathology (P=0.001).
As is known from published data [19], if a P. aeruginosa corneal
infection is left to proceed for a longer period of time in C57Bl6
mice, perforation of the cornea occurs. This outcome was
observed in an additional group of C57BL6 control mice, but
not in MIF KO mice in the C57Bk6 background (Fig. 1C). This
reduced pathology in the MIF KO mice was observed across a
range of bacterial challenge doses from 1610
6 (data not shown) to
1610
7 cfu/mouse eye (Fig. 1C). The improved outcomes in MIF
KO mice was also obtained with P. aeruginosa strain PAO1 48 h
following infection (Figure S1).
MIF deficiency regulates inflammatory responses during
P. aeruginosa keratitis
Since MIF regulates the pro-inflammatory responses to LPS
challenge in vitro as well as in several in vivo models, we examined
how MIF might modulate the molecular responses to P. aeruginosa
induced keratitis by measuring local cytokine production based on
prior findings as to which mediators are regulated by MIF and a
small-scale microarray analysis we performed (data not shown) on
infected corneas from WT and MIF KO mice to suggest which
cytokines might be candidates for a more thorough investigation.
A panel of five cytokines, TNF-a, IL-1b, KC, IL-6, and IL-10,
were quantified at the protein level in infected corneas harvested
from individual animals. Infected MIF KO mice had significantly
lower levels of TNF-a, IL-1b, IL-6, and KC protein in corneal
homogenates compared to corneas from infected C57Bl6 mice.
There was no difference in the levels of the anti-inflammatory
cytokine IL-10 (Fig. 2).
MIF deficiency modulates PMN infiltration to the site of
infection in the eye
To determine if differences in inflammatory responses translate
into differences in the presence of infiltrating PMNs during
infection, histologic observations were carried out. C57Bl/6 mice
showed destruction of the epithelial layer of the cornea and
elevated infiltration of PMNs in the aqueous chamber. In contrast,
in the MIF KO mice, there were less infiltrating PMNs, less
edema, and no destruction of the epithelial layer (Fig. 3A and 3B)
when either strain 6294 or PAO1 were used to induce infections.
The pathology in the C57Bl/6 corneas was consistent with an
acute P. aeruginosa infection.
The findings on bacterial levels and PMN infiltration into the P.
aeruginosa-infected cornea indicated that MIF promoted PMN
infiltration leading to more pathology while also inhibiting the
clearance of this microbe from the cornea. To determine a
potential cellular basis for the improved outcomes in MIF-deficient
mice, we compared the opsonic killing activity of PMNs obtained
from MIF-sufficient and MIF-deficient animals. MIF-deficient
PMNs phagocytosed P. aeruginosa strain PAO1 more efficiently that
MIF-sufficient PMNs, as evident by the decreased number of P.
aeruginosa recovered from the PMN/bacteria mixture at the end of
the experiment (Fig. 3D).
MIF promotes expression of proinflammatory cytokines
in primary corneal epithelial cells
Since it is well documented that human epithelial cells
participate in neutrophil recruitment in response to infection, we
determined if MIF affects IL-8 synthesis by corneal epithelial cells
[20,21,22]. Primary human corneal epithelial cells were grown to
confluence, treated with either a siRNA to knock-down MIF or
with a control (control) siRNA (Fig. 4A). Seventy-two h after the
knock-down cells were infected with P. aeruginosa strain 6294
(Fig. 4B). We also evaluated the effect of adding recombinant MIF
(rMIF) to cells treated with siRNA for MIF. Tissue culture
supernatants were collected and IL-8 levels measured by ELISA.
Author Summary
Pseudomonas aeruginosa can induce infections that lead to
a rapid loss of visual function. The current therapy includes
antibiotic treatment which reduces the bacterial burden;
nevertheless, tissue damage occurs as a result of an
uncontrolled inflammation. Therefore, new therapeutic
approaches are needed that will combine antimicrobial
treatment with anti-inflammatory treatment. Our experi-
ments have uncovered that mice deficient for macrophage
migration inhibitory factor (MIF) recovered from acute
bacterial infection more efficiently than wild-type control
mice. This improvement was manifested as improved
bacterial clearance, and decreased inflammatory responses
in the MIF knockouts when compared to P. aeruginosa-
infected wild-type control mice. We find that treatment of
the infected mice with small molecule inhibitor of MIF
activity after the onset of the infection promoted recovery
from disease. This approach will facilitate generation of
novel treatment strategies for bacterial keratitis.
MIF and Pseudomonas aeruginosa
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treated cells, whereas IL-8 production was much less pronounced
in MIF siRNA-treated cells (ANOVA, P,0.01) (Fig. 4B).
Treatment with rMIF reconstituted P. aeruginosa-induced IL-8
production in MIF-siRNA treated cells. Protein concentrations in
cellular lysates were determined and no differences found,
indicating no major changes in cellular numbers occurred during
the experiments.
We next analyzed the effect of a small molecule inhibitor of the
MIF tautomerase activity, 4-IPP, on P. aeruginosa-induced
inflammation. Published studies have demonstrated that 4-IPP
forms covalent complexes with MIF, and, hence, inhibits MIF
activity [23]. Treatment with 4-IPP almost completely abolished
IL-8 synthesis. This effect of 4-IPP was observed at concentrations
of 200 mM and 400 mM (Fig. 4C). Since we were concerned that
the 4-IPP treatment could induce cellular apoptosis due to the
documented role of MIF in promoting cell survival [24,25], we
next analyzed lysates obtained from non-treated and P. aeruginosa
strain 6294 infected cells in the presence or absence of 400 mM4 -
IPP and probed for activated caspase 3 as a marker for apoptosis.
At 6 h post infection we did not observe activation of caspase 3,
however some activation was detected at 24 h post-infection
(Figure S2). Hence, we have performed the majority of our
infection experiments within 6 h post-infection. When epithelial
cells were stimulated by P. aeruginosa strains 6294 or PAO1 both
IL-1b and IL-6 secretion was abolished in the presence of the MIF
inhibitor (Fig. 4D).
As P. aeruginosa bacteria found in the cornea during infection are
mostly intracellular, we determined if MIF modulated the uptake
of bacteria by corneal epithelial cells using in vitro invasion assays.
Inhibition of MIF by either siRNA treatment or by treatment with
small molecule inhibitor 4-IPP, significantly decreased the
Figure 2. Inflammatory responses in the corneas of MIF KO and C57Bl6 mice infected with P. aeruginosa strain 6294. Groups of 7 MIF
KO mice and C57Bl6 mice were infected with 1610
6 cfu placed onto scratch-injured eyes. Mouse corneas were harvested at 48 h after infection,
washed in F12 media, homogenized in PBS containing a mix of protease inhibitors and supplemented with 0.5% Triton to disrupt plasma
membranes. The levels of mouse cytokines in corneal lysates were simultaneously measured using a Meso Scale Discovery (MSD) multiplex 7-spot
electrochemiluminescence (ECL) assay. The levels of cytokines measured in the different groups were compared with the Mann-Whitney U test. TNF-
a, IL-1b, IL-6 and KC were significantly decreased in MIF KO with C57Bl6 mice P=0.004, P=0.001, P=0.01, P=0.04 respectively.
doi:10.1371/journal.ppat.1000826.g002
Figure 1. MIF KO mice are protected from P. aeruginosa-induced infection. A. Extracellular (left) and intracellular (middle) levels of P.
aeruginosa strain 6294 and associated pathology scores (right) determined 24 h following infection with 10
6 cfu onto eyes of MIF KO or WT C57Bl6
mice. Points indicate values for individual mice, bars the medians. Data are from a representative experiment out of two performed. B. Extracellular
(left) and intracellular (middle) cfu of P. aeruginosa strain 6294 at 48 h following infection. Significantly different levels of 6294 were detected both
extracellularly (left) (P=0.0003), intracellularly (middle) (P=0.0003) as were differences in pathology scores (right; P=0.001). P values by Mann-
Whitney U test. The data are from one representative experiment out of three performed. C. Significantly higher corneal pathology scores induced by
P. aeruginosa at 96 h (P=0.007) and 120 h (P=0.009) after challenge. Points indicate individual mice, bars the medians. Data are from a
representative experiment out of two performed.
doi:10.1371/journal.ppat.1000826.g001
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C57Bl6 mice (N=7) and MIF KO (N=7) were infected with P. aeruginosa strain 6294 and the eyes harvested at 48 h post-challenge. Tissue was
embedded in paraffin, sectioned and stained with H&E. Representative images were collected at 206magnification. The inset in the magnified area
depicts the morphological changes after 48 h of infection using 406magnification. B. Representative images of H&E tissue sections from C57Bl6
mice and MIF KO infected with P. aeruginosa strain PAO1 (206magnification). C. PMN recruitment was quantified by counting PMNs per field of
vision in three consecutive sections from 3 individual mice. D. Opsonophagocytosis of P. aeruginosa strain PAO1 by PMNs from WT C57Bl6 and MIF
deficient mice. Bone marrow derived MIF-deficient and MIF-sufficient PMNs were exposed to P. aeruginosa PAO1 in the presence of complement and
murine sera for 3 h at 37C. Upon completion of incubation PMNs were lysed and bacterial levels in the reaction quantified (p=0.04, P values
determined by an unpaired Student t-test).
doi:10.1371/journal.ppat.1000826.g003
MIF and Pseudomonas aeruginosa
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Figure 4. Corneal epithelial cells produce less IL-8, IL-6, IL-1b after infection with P. aeruginosa strain 6294 when MIF levels are
reduced or MIF tautomerase activity inhibited. A. 1610
6 corneal epithelial cells were seeded in 6-well plates, transfected with control siRNA or
MIF siRNA, and MIF levels in the culture supernatants were measured by ELISA. B. 1610
6 corneal epithelial cells were infected with P. aeruginosa at an
MOI 25 for 60 min after 72 h of initial treatment with either control siRNA or MIF siRNA. Recombinant MIF was added to an additional series of wells,
pretreated with MIF siRNA. Tissue culture supernatants were collected 6 h post infection and the levels of IL-8 measured by ELISA. The background IL-
8 levels were subtracted. Results are representative of duplicate experiments. C. Corneal epithelial cells were pre-treated with 100, 200 or 400 mMo f
4-IPP prior to infection with P. aeruginosa strain 6294. The inhibitor was maintained during the infection and for 6 h post-infection. Supernatants were
collected and IL-8 quantified by ELISA. The background levels were subtracted. The results are representative of duplicate experiments. P values
MIF and Pseudomonas aeruginosa
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epithelial cells (Fig. 5). These findings suggest that MIF modifies
epithelial responses facilitating bacterial entry in the epithelial cells
and thus inhibits the niche that P. aeruginosa uses to survive and
escape from PMNs recruited to the eye in response to infection.
Recombinant MIF restores the wild-type response to P.
aeruginosa-induced acute bacterial keratitis in MIF KO
mice
To verify that MIF was the major factor responsible for the
reduced infectious complications of P. aeruginosa keratitis in MIF
KO mice, reconstitution experiments were performed. One mgo f
rMIF administered topically onto the eye of infected MIF KO
mice restored the wild-type response to infection with P. aeruginosa
strain 6294 (Fig. 6). This increased bacterial burden in the
reconstituted MIF KO correlated with elevated pathology scores,
indicative of increased susceptibility to infection.
Inhibition of MIF activity by 4-IPP promotes recovery
from P. aeruginosa-induced keratitis
To analyze the effect of MIF inhibition during P. aeruginosa-
induced keratitis, cohorts of C57Bl6 mice were infected with
5610
5 cfu/mouse of P. aeruginosa strain 6294 and treated topically
with gentamicin starting 24 h post-infection. A separate cohort of
infected C57Bl6 mice received both 4-IPP IP and gentamicin eye-
drops on the same schedule. Animals were monitored for 5 days to
analyze recovery from infection and the infected corneas were
harvested to quantify the intracellular and extracellular bacteria.
Mice that received the 4-IPP and gentamicin treatment cleared P.
aeruginosa more efficiently than did the group treated only with
Figure 5. 4-IPP inhibits P. aeruginosa invasion of corneal epithelial cells. A. Corneal epithelial cells were pre-treated with MIF siRNA or
control siRNA for 72 h prior to the experiment. Invasion assays were carried out with P. aeruginosa strain 6294 at a MOI 10 for 3 h. Cells were washed,
treated with gentamicin to kill all extracellular bacteria, lysed and plated. The results are representative of triplicate experiments. P values determined
by an unpaired Student t-test. B. Corneal epithelial cells were pre-treated with 400 mM of 4-IPP prior to infection with P. aeruginosa strains 6294 or
PAO1 and the inhibitor was maintained during the infection. After 3 h, cells were washed, treated with gentamicin, lysed and plated. The results are
derived from triplicate experiments. P values determined by an unpaired Student t-test.
doi:10.1371/journal.ppat.1000826.g005
determined by an unpaired Student t-test. D. Corneal epithelial cells were treated with 400 mM of 4-IPP prior to infection with P. aeruginosa strain
6294 or PAO1. The inhibitor was maintained during the infection and for 6 h post-infection. Supernatants were collected and IL-1b, IL-6, IL-8
quantified by ELISA. The background levels were subtracted. The results are representative of duplicate experiments. P values determined by an
unpaired Student t-test.
doi:10.1371/journal.ppat.1000826.g004
MIF and Pseudomonas aeruginosa
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extracellular and intracellular cfu recovered from the corneas,
and decreased pathology scores (Fig. 7).
Discussion
Pseudomonas aeruginosa causes serious corneal disease, associated
with acute ocular inflammation. Both bacterial and host factors
contribute to the pathogenesis of P. aeruginosa keratitis, indicating
that the optimal interventions for this infection will involve both
control of bacterial levels and modulation of inflammation to limit
pathology while not compromising bacterial clearance. Here, we
demonstrated that a master regulator of inflammation–MIF–
promoted both pathology associated with P. aeruginosa corneal
infection and inhibited bacterial clearance as shown by outcomes
in MIF-KO mice which had decreased bacterial burdens in the
corneas, decreased inflammation, and decreased neutrophil
infiltration compared to MIF-sufficient WT mice. These improved
outcomes in MIF-deficient mice could be reversed by treating P.
aeruginosa-infected eyes with rMIF and could be mimicked in WT
mice treated with the MIF inhibitor 4-IPP. Thus, it appears that
one host molecule makes a major contribution to both aspects of
disease resulting from P. aeruginosa corneal infection, indicating a
high potential for ameliorating the consequences of this infection
by therapies that target the activities of MIF.
To define mechanisms associated with the effects of MIF in P.
aeruginosa keratitis we used in vitro studies to show that reduction
of MIF levels by siRNA treatment or by the use of the
tautomerase inhibitor of MIF, 4-IPP, results in decreased
production of IL-8, IL-1b, and IL-6 by human corneal epithelial
cells after infection. Consistent with this finding, the absence of
MIF in vivo also reduced inflammatory responses to P. aeruginosa
during experimental murine corneal infection. Furthermore, we
also found that PMNs from MIF-deficient mice had a better
innate ability to kill P. aeruginosa in an in vitro opsonic-killing
assay, indicating a likely cellular basis for the better control of
infection in thee animals. Of note, Niederkorn and colleagues
[18] found that MIF inhibits perforin release by NK cells and
inhibits NK cell motility, indicating a contribution of MIF to the
immune-privileged status of the eye. Thus, it appears in the
basal state MIF limits cellular activation, but a consequence of
this is that the responses to infection are dampened and the
increased infiltration of PMN into the infected cornea that is
needed to deal with the increased bacterial burdens results in
more tissue pathology. A similar improved outcome from P.
aeruginosa lung infection was reported for MIF-deficient mice
[11].
Successful recovery form acute bacterial infection depends on
timely recruitment of neutrophils. PMNs are present in the cornea
and aqueous chamber in MIF deficient mice at reduced levels
when compared to infected WT control mice, yet, there are
sufficient numbers of PMNs recruited in the MIF KO to clear
bacteria, as demonstrated by the decreased levels of P. aeruginosa
measured at 48 h after the onset of infection. Hence, MIF
deficiency both reduces pathology during infection and still allows
for sufficient host responses to clear bacteria. Our data suggests
that in infected mouse corneas, inflammatory mediators such as
KC or MIP2 are initially released by corneal epithelial cells or
keratocytes which in turn recruit PMNs to effectively handle
bacterial infections in the eye [26], a process that occurs in the
infected MIF KO mice leading to resolution of infection. In
contrast, in the infected C57Bl6 mice these mediators are
produced at higher levels and become part of a classic
hypersensitivity response that contributes to tissue damage and
elevated pathology [27,28]. Taken together these data suggest that
by modulating the level of inflammation occurring in the eye
triggered by P. aeruginosa infection it is possible to promote
expression of proinflammatory mediators sufficient to control
infection while also preventing inflammation-induced corneal
pathology and associated loss of vision.
Materials and Methods
Mice
Ethics Statement: All studies were performed in accordance
with the Harvard Medical School Institutional Animal Care and
Use Committee guidelines (approval date 10/14/2008; number
IACUC 02432).
Breeding pairs of mif knock-out (KO) mice were a kind gift
from Dr. C. Gerard (Children’s Hospital Boston). Control mice
Figure 6. rMIF restores sensitivity to P. aeruginosa-induced disease in MIF KO mice. A. Topical treatment of corneas from P. aeruginosa-
infected MIF-deficient mice resulted in bacterial levels comparable to that achieved in infected WT C57Bl6 mice (P.0.05 ANOVA and Dunnett’s test)
while MIF KO mice had reduced levels of P. aeruginosa in the tissue. B. Pathology scores. MIF KO presented with reduced pathology scores (P,0.05,
ANOVA and Dunnett’s test). Points indicate values from individual mice, bars the medians. The data are from one representative experiment out of
two performed.
doi:10.1371/journal.ppat.1000826.g006
MIF and Pseudomonas aeruginosa
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and bred in the Channing Laboratory Animal Care Facilities.
Mice were housed and bred in one of the Harvard Medical Area
Animal Care Facilities.
Bacterial strains and inocula
P. aeruginosa strains PAO1 and 6294 were used throughout these
experiments. Effects from low dose (5610
5 cfu/eye) and high dose
(1610
7 cfu/eye) inocula were evaluated to determine the doses to
use in the in vivo infection studies. Generally, the bacterial strains
were grown o/n at 37C on Tryptic Soy Broth agar plates prior to
experiments.
Infection model
The experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of the Harvard Medical
Area Office for Research Subject Protection and were consistent
with the Association for Research in Vision and Ophthalmology
guidelines for studies in animals. Infections were carried out as
described previously [29]. Mice were anesthetized with keta-
mine and xylazine injections. Three 0.5 cm scratches were
made on the cornea and an inoculum of P. aeruginosa delivered in
5 ml onto the eye. Mice remained sedated for about 30 min. For
evaluation of corneal pathology, daily scores are recorded by an
observer unaware of the experimental status of the animals
based on a the following scoring system using a graded scale of 0
to 4 as follows: 0, eye macroscopically identical to the uninfected
contra-lateral control eye; 1, faint opacity partially covering the
pupil; 2, dense opacity covering the pupil; 3, dense opacity
covering the entire anterior segment; and 4, perforation of the
cornea, phthisis bulbi (shrinkage of the globe after inflammatory
disease), or both. To determine the levels of bacteria in the
cornea 24 or 48 h after infection, mice were sacrificed, eyes
enucleated and corneas dissected from the ocular surface. To
quantify the extracellular levels of P. aeruginosa, corneas were
excised and suspended in PBS, vortexed, serial dilutions made
a n dp l a t e do nP. aeruginosa selective cetrimide plates. To measure
the intracellular levels of P. aeruginosa, the intact corneas were
placed in F12 medium containing 5% FBS and 300 mg
gentamicin/ml for 60 min, vigorously rinsed to wash away the
antibiotic and the tissue then homogenized in 0.05% Triton
X100 in 5% FBS-F12, diluted in 5% FBS-F12, and plated for
bacterial counts. For treatment, groups of mice were infected
with P. aeruginosa strain 6294, treated topically daily for 5 days
with 5 ml of a solution of 100 mg gentamicin/ml, along with
50 ml of 1 M 4-IPP injected IP. The 4-IPP was solubilized in
DMSO/corn oil [23]. Bacteria were quantified 5 days after
infection by homogenizing and plating the corneal tissue.
Reconstitution experiments
Mice were infected with P. aeruginosa strain 6294 and 1 mg
recombinant MIF (rMIF). applied topically in 5 ml at the time of
infection and subsequently every 6 h after the infection. Corneas
were harvested after 48 h of infection, treated with 300 mg
gentamicin/ml for 60 min, washed, homogenized with F12
medium containing 5% FBS and 0.05% Triton X100, diluted
and plated.
Histopathology examinations
Eyes were enucleated from euthanized mice and fixed in 4%
paraformaldehyde then embedded in paraffin. Four mm sections
were cut, and stained with hematoxylin-eosin to visualize tissue
morphology following previously used techniques [30].
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Figure 7. Treatment with 4-IPP promotes recovery from P.
aeruginosa-induced corneal infection and pathology. Groups of
C57Bl6 mice were treated with either gentamicin alone or gentamicin
and 4-IPP for 5 days after infection after which infected corneas were
harvested, homogenized, and bacteria quantified. Points indicate values
from individual mice, bars the medians. The data are from one
representative experiment out of two performed.
doi:10.1371/journal.ppat.1000826.g007
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Primary corneal epithelial cells [31] were grown in 6-well plates
in either keratinocyte SFM (Invitrogen) medium supplemented
with antibiotics, EGF, and pituitary gland extract or in MEM/F12
mix supplemented with EGF, insulin, DMSO, and cholera toxin
[31]. Confluent monolayers of corneal cells were treated for 1 h
with 4-IPP then infected with different strains of P. aeruginosa
(PAO1, 6294) at a MOI of 25 for 1 h. Following treatment for 1 h
with 300 mg gentamicin/ml, cells were re-supplemented with
growth medium. The keratinocyte SFM growth medium was
supplemented with penicillin, streptomycin, EGF, and pituitary
gland extract. 6-iodo-6-phenylpirimidine (4-IPP) was used to
inhibit MIF activity in vitro and was maintained during the
infection and gentamicin treatments. Different concentrations of
4–IPP were used, ranging from 100 mM to 400 mM. The tissue
culture supernatants were collected at 6 h and 24 h after infection
and total cell lysates were prepared in RIPA buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 1% SDS, and Complete Mini Protease Inhibitor
Cocktail (Roche Diagnostics).
Epithelial cell invasion assay
P. aeruginosa strains 6294 or PAO1 were grown to mid-log phase
in TSB for 2 h at 37C and used for invasion assays. Bacterial cells
were washed and suspended in F12 medium. Human primary
corneal epithelial cells were grown to confluence in 6 well plates in
F12 medium and infected with the P. aeruginosa strains at a MOI of
25 for 3 h. After the infection, cells were washed with F12, then
treated with 300 mg or 400 mg gentamicin/ml for 1 h to kill the
extracellular bacteria depending on the activity of the antibiotic.
After washing away the antibiotic, cells were lysed in 1% Triton X
100 in MEM and the lysates were diluted then plated on cetrimide
plates to enumerate intracellular bacteria.
Cytokine analysis
Commercially available ELISA assays (R&D Systems) were
used to determine the levels of cytokines (IL-8, IL-6) produced by
P. aeruginosa infected primary human corneal cells. Mouse
cytokines were measured using a Meso Scale Discovery (MSD)
multiplex 7-spot electrochemiluminescence (ECL) assay and
outputs measured by an ultra low noise charge-coupled device
(CCD) Imager 2400 (Meso Scale Discovery, Gaithersburg, MD,
USA). The cytokines measured included interleukin (IL)-1b, IL-6,
IL-12p70, IL-10, IFNc and the alpha chemokine neutrophil
attractant and activator CXCL1/GRO (also known as KC). The
MSD ECL platform has been previously validated against cytokine
standards recommended by WHO and U.K. National Institute for
Biological Standards and Control (NIBSC) and by comparison to
traditional ELISA [32].
siRNA experiments
Production of MIF by the primary corneal epithelial cells was
reduced by MIF-specific siRNA treatment. Briefly, cells were
transfected with MIF-specific or control siRNA (On-target plus
SMART pool; Dharmacon) by incubating with a transfection
mixture that consists of 50 nM siRNA (Dharmacon) and 6 ml
Oligofectamine (Invitrogen) in 1 ml of Opti-MEM (Gibco) for
48 h, after which the cells were maintained with regular growth
medium. Epithelial cells were infected with P. aeruginosa (strain
6294 or strain PAOI) 48 h to 72 h after siRNA treatment. A non-
siRNA treated control was also included to determine if there is an
effect on inflammatory gene expressing from the control siRNA.
Purification of PMNs and opsonophagocytic assays
Murine PMNs were purified from bone marrow by flushing the
cells out of the tibias and femurs with 3 ml HBSS (Hanks balanced
salt solution) buffer (Invitrogen). Cells were pelleted by centrifu-
gation at 380 g for 10 min at tabletop centrifuge; resuspended in
1 ml HBSS and overlayed on the top of a Histopaque gradient
composed of 3 ml Histopaque 1119 (Sigma) and 3 ml Histopaque
1077 (Sigma). Cells were centrigufed for 30 min at 700 g, room
temperature, without a brake. Neutrophils were collected from the
interface of the Histopague 1077 and 1119, transferred to a fresh
tube and washed three times by adding 10 ml og HBSS. Viable
cells were enumerated by tryptan blue exclusion technique.
Opsonophagocytic assays were performed by mixing 100 mlo f
2.5610
6 PMN with 100 ml of 400 fold dilution of P. aeruginosa
grown in TSB to reach mid-log phase as estimated by OD 650
reading of 0.4. 100 ml of Rabbit complement sera (Sigma) and
100 ml of freshly harvested mouse sera from either C57Bl6 or MIF
KO mice were added to the sample mixture as appropriate. The
reaction was incubated for 90 min at 37uC with rotation. After
completion of the incubation an aliquot was taken and lyzed with
0.05% Tween 20/TSB. Bacteria were enumerated by plating on
P. aeruginosa selective cetrimide plates.
Supporting Information
Figure S1 MIF KO mice are protected from P. aeruginosa PAO1-
induced keratitis 48 h after infection. Extracellular and intracel-
lular levels of P. aeruginosa strain PAO1 48 h following infection
with 10
6 cfu onto the eyes of WT C57/Bl6 or MIF KO mice.
Points indicate individual mice, bars the medians. Significantly
different levels of PAO1 were detected both extracellularly
P=0.03 and intracellularly P=0.0025, Mann-Whitney U test.
Pathology scores. P=0.008, Mann-Whitney U test. The data are
from one representative experiment out of three performed.
Found at: doi:10.1371/journal.ppat.1000826.s001 (1.25 MB EPS)
Figure S2 Cellular apoptosis during infection and 4-IPP
treatment. A. Corneal epithelial cells were infected with either P.
aeruginosa 6294 in the presence of 4-IPP or DMSO control
treatment and cellular lysates were collected at either 6 h post-
infection or 24 h post-infection. Lysates were loaded on 4–12%
SDS-PAGE gel, blotted and developed with antibody to activated
caspase-3 or antibody to actin. B. Corneal epithelial cells were
infected with either P. aeruginosa 6294 in the presence of 4-IPP or
DMSO control treatment, 6 h post-infection cells were trypsinized
and live/dead bacteria were quantified by Tryptan Blue exclusion
assay. The percent of live cells were plotted.
Found at: doi:10.1371/journal.ppat.1000826.s002 (0.66 MB EPS)
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